Racial and ethnic disparities in financial barriers among overweight and obese adults eligible for semaglutide in the United States
Because tirzepatide produces more weight loss than semaglutide (dual receptor versus single receptor), and because orforglipron is a single GLP-1 receptor agonist, there was an expected gap in potency
The gastrointestinal tract contains GLP-1 receptors in various regions
One patient achieved 33 percent total body weight loss over 115 weeks, but 91.2 percent of that weight loss came from fat, with only 8.7 percent from lean tissue
This large study, which included more than 17,500 patients, showed that adding semaglutide to their standard care significantly reduced the risk of heart attack, stroke, or death by cardiovascular disease
2024;16(16) doi: 10.3390/nu16162809